CLINICAL_TRIALS
trial_result
· 2025-07-01
Clinical Trial Update: A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis [Phase 2]
Summary
A Phase 2 study evaluating guselkumab for new-onset or relapsing giant cell arteritis has been terminated, with results posted on 2025-07-01.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Giant Cell Arteritis | Phase 2 | Status: TERMINATED | Results posted: 2025-07-01